MYRIAD GENETICS (MYD DU) stock market data APIs
€3.7739
-0.14(-3.7%)
as of June 3, 2026
Try our APIs with
free plan!
MYRIAD GENETICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for MYD.DU.
Prev. Close
3.7739
Open
3.6386
High
3.7895
Low
3.5761
52 wk Range
3.001-7.2
Market Cap
1 751 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MYRIAD GENETICS data using free add-ons & libraries
Get MYRIAD GENETICS Fundamental Data
MYRIAD GENETICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-05
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MYRIAD GENETICS News
New
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Myriad Genetics, Inc. SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the app...
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
Myriad Genetics, Inc. MYGN recently announced that it would launch the Prolaris + AI Test at the end of this month. It will be the first prostate cancer biomarker test to combine clinical-pathologica...
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics, Inc. MYGN sits at the center of a classic value-versus-execution debate. The stock is currently valued at about 0.4x forward 12-month sales, well below the levels cited for the Zacks ...
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics, Inc. MYGN entered 2026 with a strategy centered on its Cancer Care Continuum and a busy oncology launch schedule. The first quarter showed progress, even with stable total testing vol...
Get MYRIAD GENETICS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
